Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company’s progress ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.